Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Amyloid Precursor Protein (APP) Overview 6
Therapeutics Development 7
Amyloid Precursor Protein (APP) - Products under Development by Stage of Development 7
Amyloid Precursor Protein (APP) - Products under Development by Therapy Area 8
Amyloid Precursor Protein (APP) - Products under Development by Indication 9
Amyloid Precursor Protein (APP) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Amyloid Precursor Protein (APP) - Products under Development by Companies 12
Amyloid Precursor Protein (APP) - Products under Development by Universities/Institutes 14
Amyloid Precursor Protein (APP) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 19
Amyloid Precursor Protein (APP) - Companies Involved in Therapeutics Development 21
CereSpir Incorporated 21
QR Pharma, Inc. 22
Amyloid Precursor Protein (APP) - Drug Profiles 23
Antisense RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
ARN-2955 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
ARN-2966 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Bisnorcymserine - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
CSP-1103 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Posiphen - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Small Molecules to Inhibit Amyloid Beta Protein for Alzheimer's Disease - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
tropisetron hydrochloride - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Amyloid Precursor Protein (APP) - Dormant Projects 35
Amyloid Precursor Protein (APP) - Featured News & Press Releases 36
Jul 14, 2015: CereSpir Obtains New Patent From USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease 36
Jul 01, 2015: CereSpir Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease 36
Nov 10, 2014: Buck Institute's First Clinical Trial Underway in Australia 37
Jun 09, 2014: Aria Announces Promising Results with Alzheimers Compound 37
Oct 10, 2013: QR Pharma and UCLA Awarded $3 Million USARMY Grant to Test Posiphen in Rat Models of Concussion and Blunt Head Trauma 38
Jul 26, 2013: CERESPIR INCORPORATED IS PLEASED WITH POSITIVE INTERIM PHASE 2 RESULTS FOR CHF 5074 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT, PRESENTED BY CHIESI AT THE AAIC 2013 MEETING IN BOSTON 38
Oct 22, 2012: QR Pharma's Posiphen Restores Brain Function, Cognition And Memory In Transgenic Alzheimer Mice 39
Jul 24, 2012: QR Pharma Starts Phase I Clinical Study For Bisnorcymserine 40
Jul 17, 2012: QR Pharma Announces Publication On Posiphen Clinical Trials Showing Promise For Alzheimer's Patients 40
Jul 10, 2012: QR Pharma To Present Clinical Data On Posiphen At Alzheimer's Association International Conference 41
Mar 06, 2012: QR Pharma Receives $468,000 From Michael J. Fox Foundation To Test Posiphen For Treatment Of Parkinson's Disease 41
Oct 13, 2011: QR Pharma Reports Results From SBIR Grant By NIA/NIH To Study Posiphen And Metabolites In Various Models 42
Jul 12, 2011: QR Pharma To Present Poster At International Conference On Alzheimer's Disease 42
Jun 02, 2011: QR Pharma To Present At Annual World Pharma Congress On Parkinson's Disease 43
Jan 19, 2011: QR Pharma To Present Poster At 44th Winter Conference On Brain Research 43
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46



List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 17
Number of Products by Stage and Route of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by CereSpir Incorporated, H2 2016 21
Pipeline by QR Pharma, Inc., H2 2016 22
Dormant Projects, H2 2016 35



List of Figures

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Actions, H2 2016 17
Number of Products by Stage and Routes of Administration, H2 2016 18
Number of Products by Molecule Types, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 19

Companies Mentioned
CereSpir Incorporated
QR Pharma, Inc.